Facilitating the decrease in fibromyalgic pain during metabolic rehabilitation: an essential role for soft tissue therapies

Recent evidence indicates that fibromyalgia (FMS) is a manifestation of impaired metabolism. In most cases, the cause is primarily inadequate thyroid hormone regulation of cell function. The measurable features of FMS can be improved or relieved in most patients through therapy that is best termed ‘metabolic rehabilitation’. For many patients undergoing metabolic rehabilitation, however, FMS pain scores normalize only after soft tissue treatment controls or eliminates noxious neural input from the musculoskeletal system to the central nervous system. Our studies and clinical experiences convince us that effective soft tissue therapy can expedite the typical patient's improvement or recovery. Neglecting to use such therapy can hinder recovery, even when the patient undergoes expertly conducted metabolic rehabilitation. This paper describes the probable mechanisms by which musculoskeletal lesions can sustain FMS pain, and gives guidelines for treating the FMS patient's soft tissues to facilitate the reduction of pain during metabolic rehabilitation.